2-DG’s scientific history spans seven decades, making it one of the longest-studied metabolic research compounds. Understanding this history puts modern oncology trials in context.

In the 1950s, 2-DG was first studied as an antiviral agent. Researchers observed that it inhibited viral replication in cell culture — an effect later attributed to its interference with glycoprotein synthesis. This early work established 2-DG’s biological activity and safety profile in animal models.

From the 1970s through the 1990s, 2-DG became a core tool in cancer metabolism research. Its ability to selectively starve glucose-dependent cancer cells while sparing normal cells made it an attractive research candidate. Hundreds of in vitro and animal model studies established its mechanism and demonstrated consistent anti-tumour effects.

Human clinical trials began in the 2000s. A phase I trial published in 2004 in Clinical Cancer Research established the maximum tolerated dose in humans and confirmed the expected dose-limiting toxicity: hypoglycaemia-like symptoms. Phase I/II combination trials with radiation have followed, particularly in glioblastoma.

2-DG is not an approved cancer treatment. The clinical trial data is promising but limited. The preclinical evidence base is one of the most extensive of any metabolic research compound.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.